Eating a normally varied diet · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions
The review found no eligible studies for this question.
1 finding from 1 review
Restoration of sexual activity · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions
The review found no eligible studies for this question.
1 finding from 1 review
Reduction in number of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions
The review found no eligible studies for this question.
1 finding from 1 review
Reduction in severity of flares · People of any age with erosive lichen planus affecting the oral, anogenital, and/or oesophageal regions
The review found no eligible studies for this question.
1 finding from 1 review
Effect on later sexual function · symptomatic or early postmenopausal women1.
1 finding from 1 review
Effect on later sexual function · Postmenopausal women
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · children and adults with predominantly mild to moderate asthma
Summary of findings table ‐ Vitamin D showed no clear difference in proportion of participants with one or more exacerbations treated… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Reslizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Reslizumab subcutaneous (SC) showed no clear difference in rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Benralizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma
Mepolizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
The review found no eligible studies for this question.
1 finding from 1 review
Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis
1 finding from 1 review
Intervention not reported
Mean change from baseline in number of topical or systemic steroids at 6 months*2 · Participants with a diagnosis of JIA and uveitis who are aged 2 to 18 years old
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Severe exacerbations (requiring ED visits or systemic steroids, or both) Number of people having ≥ 1 exacerbations requiring an ED visit or systemic steroids, or both. Classification varied across studies. Weighted mean study duration: 35 weeks · adults and children with chronic asthma
Macrolides probably leads to lower severe exacerbations (requiring ED visits or systemic steroids, or… compared with placebo (moderate certainty).
1 finding from 1 review
Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found